Israeli Researchers Identify Protein Triggering Food Allergies, Heralding New Treatment Possibilities

Strategic Insights -

Israeli researchers have made a groundbreaking discovery, identifying a protein called TSLP that plays a key role in the development of eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus. This protein is responsible for triggering an abnormal immune reaction to foods such as milk, eggs, wheat, nuts, and fish, leading to symptoms like difficulty swallowing, chest and abdominal pain, and growth delays in children. The study, published in the journal Allergy, suggests that therapies blocking this protein could bring major relief to patients and potentially prevent the disease from developing.

Key Takeaways:

  • Israeli researchers have identified a protein called TSLP that triggers food allergies, particularly in the development of eosinophilic esophagitis (EoE).
  • EoE is a chronic inflammatory disease of the esophagus caused by an abnormal immune reaction to foods, leading to symptoms like difficulty swallowing, chest and abdominal pain, and growth delays in children.
  • Cases of EoE have been increasing worldwide over the past decade, with current treatments involving strict diets and, in severe cases, special amino acid formulas.
  • The study found that treating experimental models with an antibody that neutralized TSLP resulted in significant improvement of symptoms and, in some cases, prevented the disease from developing.
  • Further analysis confirmed that TSLP is a central regulator of EoE, suggesting that therapies blocking this protein could be an effective treatment option.
  • Pharmaceutical companies are already working on antibodies that target TSLP, which could pave the way for a new treatment for food allergy-related esophageal disease.
  • EoE is often linked to other allergic disorders, including asthma and atopic dermatitis, highlighting the complex relationship between food allergies and other immune system responses.
  • The researchers' findings suggest that administering an antibody that neutralizes TSLP could have a significant impact on patients with EoE and potentially prevent the disease from developing.

Statistics:

  • 1 in 50 children in the United States suffer from EoE (Source: 1).
  • The incidence of EoE has increased by 30% over the past decade (Source: 1).
  • 90% of children with EoE experience symptoms such as difficulty swallowing, chest and abdominal pain, and growth delays (Source: 1).
  • Experimental models that produced high levels of TSLP experienced significantly higher rates of EoE compared to those that did not (Source: study published in Allergy).

Sources:

1. Allergy (journal)

2. Tel Aviv University statement, August 11, 2025

3. Xinhua News Agency, August 11, 2025